A recent study found that TIGIT blockade or deficiency in hepatitis B surface antigen (HBsAg) transgenic mice could promote the development of HCC by reversing the adaptive immune tolerance of hepatic CD8+ T-cells to HBsAg [60]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.